No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SRPT Sarepta Therapeutics
- 115.620
- -0.930-0.80%
Close Apr 19 16:00 ET
- 115.550
- -0.070-0.06%
Post 19:38 ET
10.85BMarket Cap-19934P/E (TTM)
117.740High114.370Low641.24KVolume116.550Open116.550Pre Close74.14MTurnover0.72%Turnover RatioLossP/E (Static)93.86MShares159.89052wk High12.63P/B10.36BFloat Cap55.25052wk Low--Dividend TTM89.61MShs Float181.830Historical High--Div YieldTTM2.89%Amplitude2.598Historical Low115.625Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
As More Rare Disease Therapies Launch, Their Prices Are Rising
10 Unstoppable Stocks That Will Make You Richer
Unusual Options Activity: SRPT, C and Others Attract Market Bets, SRPT V/OI Ratio Reaches 66.7
EST Apr 11th Morning Delivery - In the last two hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Sarepta Therapeutics' (NASDAQ:SRPT) Investors Will Be Pleased With Their Respectable 72% Return Over the Last Three Years
One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Sarepta Therapeutics, Inc. (NAS
Sarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for Elevidys
Comments
Analysts see the shortened timeline and absence of an advisory committee meeting as positive signs for unrestricted approval. The FDA's eagerness to expand the label and transition from accelerated to traditional approval is evident in the expedited review timeline. This could set a precedent for other gene therapies seeking FDA approval, despite Elevidys not meeting its primary endpoint.
1
Sarepta Therapeutics' low P/S ratio reflects its poor revenue outlook. The market anticipates limited growth, hence the reduced stock price. Even a recent share price surge couldn't bring the P/S to industry median. A strong share price rise seems unlikely under these conditions.
ColumnsToday's Morning Movers and Top Ratings: GOOGL, AMD, TSLA, SBUX and More
Morning Movers
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
ColumnsSeveral Biotech Stocks Have Been Hitting New Highs Since the Start of the Year, It's Biotech Industry Time to Shine
The promise for a bright 2024 comes after two years of abysmal performance of biopharma stocks. The S&P Biotechnology Select Industry Index surged 43% from its recent low in October 2023, reaching a new high since April 2022.
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
8
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg